- Zodiac Partners II, an acquisition entity of activist fund Camac Fund, LP, has launched an unsolicited all-cash tender offer for all shares of Destination XL Group (DXLG) at $0.82 per share — a roughly $46 million deal that expires June 19, 2026.
- With DXLG trading at $0.68, the gross spread is about 20.6%. That is enormous by tender-offer standards, and it is a warning sign, not a free lunch.
- The spread is wide for three concrete reasons: the offer is only partly financed (about $10M of committed equity against ~$46M needed, with the rest resting on a non-binding $75M revolver term sheet), it carries a minimum tender condition plus HSR regulatory and material-adverse-effect outs, and DXL's board has unanimously recommended that shareholders reject it.
- The picture shifted on June 3, 2026: DXL terminated its competing all-stock merger with FullBeauty Brands, removing the board's stated "superior alternative" and leaving the Camac bid as the only live takeover offer on the table.
The Offer
Destination XL Group, Inc. (NASDAQ: DXLG) — the big-and-tall men's apparel retailer — is the target of an unsolicited cash tender offer from Zodiac Partners II, LLC, an acquisition vehicle controlled by activist investor Camac Fund, LP (Eric Shahinian's firm). Zodiac is offering to buy all outstanding shares at $0.82 per share in cash, valuing the equity at roughly $46 million. The offer was commenced on May 12, 2026 and, per the amended filing, is currently set to expire at 5:00 p.m. Eastern on June 19, 2026, unless extended.
Against a recent price of $0.68, the gross spread is about 20.6% — meaning the offer sits roughly 17% above where the stock trades today. On 54,810,511 shares outstanding, the $0.82 price implies an equity value of about $44.9 million (the offeror's ~$46 million headline figure also accounts for outstanding options and restricted stock units). You can read the offeror's amended terms in the Schedule TO-T/A filed with the SEC.
This is a third-party, hostile bid. Zodiac approached the DXL board privately, was rebuffed, and went directly to shareholders — so its offer is based solely on publicly available information, with no due diligence access.
Why the Spread Is So Wide
A 20.6% gross spread on a cash deal is not normal. Friendly, fully financed, signed merger deals typically trade at spreads of 1–5%. When a spread blows out this far, the market is pricing in a real chance the deal never closes. Here, three specific problems explain the gap.
1. The financing is not locked down
This is the single biggest issue. According to DXL's board, Zodiac has committed only about $10 million of equity against the roughly $46 million it needs. The balance depends on a non-binding, indicative $75 million revolving credit facility term sheet (reportedly with Eclipse Business Capital) — a term sheet is a statement of interest, not a funding commitment. Committed equity covers only about 22% of the consideration. Until Zodiac produces funds-certain financing, there is a genuine risk it cannot actually pay for the shares it is asking investors to tender.
2. The conditions favor the buyer
The offer is conditioned on a minimum tender of more than 50% of outstanding shares, clearance under the Hart-Scott-Rodino (HSR) antitrust waiting period, and a broad material-adverse-effect provision. Each is a lever the offeror can pull to walk away or renegotiate. With the board urging rejection, clearing a greater-than-50% minimum from a fragmented shareholder base is a tall order.
3. The board says no
On May 26, 2026, DXL's board unanimously recommended that shareholders reject the offer in its Schedule 14D-9. The board argues the price fails to reflect the company's intrinsic value, points to the financing risk above, and flags the opportunistic timing — Camac had floated $1.25 per share back in January 2026 before cutting its public bid by roughly a third to $0.82, without any new due diligence.
The FullBeauty Twist
When the offer launched, the board had a ready-made counter: a separate all-stock "merger of equals" with FullBeauty Brands (FBB Holdings), signed in December 2025, under which DXL holders would have owned about 45% of a combined ~$1.2 billion-sales retailer. Zodiac attacked that deal directly, arguing it would saddle DXL with a large debt load (the combined entity carried roughly $172 million in term loans) tied to a company that had previously been through bankruptcy.
On June 3, 2026, the board terminated the FullBeauty merger on its existing terms, citing the deteriorating consumer environment and FullBeauty's debt. The two sides say they are still in "constructive discussions," but for now the board's stated superior alternative is gone. That cuts both ways for the Camac bid: it removes a competing transaction the board preferred, yet the board has still not endorsed Zodiac's offer — leaving DXLG shareholders with no recommended deal at all.
Key Terms
- Offer price: $0.82 per share, net cash, less any required withholding taxes
- Acquirer: Zodiac Partners II, LLC (acquisition entity of Camac Fund, LP; Managing Member Ziggy Gokea, Camac GP manager Eric Shahinian)
- Shares sought: All outstanding shares; 54,810,511 shares were outstanding as of March 9, 2026, implying ~$44.9 million in equity value (offeror cites ~$46 million including options/RSUs)
- Expiration: June 19, 2026, 5:00 p.m. ET, subject to extension
- Minimum tender condition: More than 50% of outstanding shares must be validly tendered and not withdrawn
- Financing: ~$10 million committed equity; remainder dependent on a non-binding, indicative $75 million revolving credit facility term sheet — no funds-certain financing in place
- Regulatory: Conditioned on expiration or termination of the HSR antitrust waiting period
- Material adverse effect: Broad MAE condition lets the offeror walk if the business deteriorates
- Board recommendation: Unanimous recommendation to REJECT (Schedule 14D-9 filed May 26, 2026)
Timeline
DXL signs an all-stock "merger of equals" with FullBeauty Brands.
Camac privately proposes $1.25 per share; the board rebuffs the approach.
Zodiac Partners II commences the unsolicited $0.82-per-share cash tender offer (~$46 million).
DXL board unanimously recommends shareholders reject the offer (Schedule 14D-9).
Zodiac files Amendment No. 1 to its Schedule TO, including the indicative $75M revolver term sheet.
DXL terminates the FullBeauty merger on its existing terms, citing the consumer environment and FullBeauty's debt.
Offer expiration (5:00 p.m. ET), subject to extension.
What Investors Should Actually Do
The math looks tempting — about $0.14 per share, or roughly 20.6%, if the deal closes near $0.68. But the market is pricing this spread wide for good reasons, and the cash sitting "on the table" is far from certain.
The base case is that this offer does not close on its current terms. The financing is incomplete, the conditions are buyer-friendly, and the board is telling shareholders to reject. The realistic bull case is not that the $0.82 offer simply closes, but that the now-terminated FullBeauty deal, combined with continued activist pressure from Camac (which has signaled it may nominate directors at the annual meeting), forces the board into a sale process or a higher bid. That is a catalyst story, not a clean merger-arbitrage spread.
Either way, this is a speculative micro-cap situation, not a low-risk arbitrage. DXLG is a thinly capitalized, ~$37 million-market-cap retailer with declining comparable-store sales (down 3.8% in the latest quarter) and a CEO transition underway. If the bid evaporates and no alternative emerges, the downside is back toward — or below — the recent $0.68 level, well off the 52-week high of $1.58. Position size accordingly, and do not treat the $0.82 figure as money you are owed.
This analysis is for informational purposes only and does not constitute investment advice. Read the complete filing and consult your own advisors before making any decisions.
Discussion
Be the first to share your thoughts on this analysis.